Professor Wong is the Head of Department of Pharmacology and Pharmacy, Co-Director of the Centre for Safe Medication Practice and Research, and holder of the Lo Shiu Kwan Kan Po Ling Professorship in Pharmacy at the University of Hong Kong. He currently leads the programme “AI and Pharmaceuticals in Non-Communicable Diseases (NCDs)” (Programme 4) at the Laboratory of Data Discovery for Health.

He is also the Co-Director of the Centre for Medication Optimisation Research and Education (CMORE) at University College London (UCL) Hospital and UCL School of Pharmacy. He has advised the Departments of Health in England and Hong Kong, the World Health Organization, the European Medicines Agency, and the pharmaceutical industry. He has over 300 peer-reviewed papers published in prominent journals and was cited among the top 1% of scholars in the Clarivate Analytics’ Essential Science Indicators in five consecutive years between 2015 and 2019.

His expertise is using big data research to investigate safety and optimum use of medications for treatment of various conditions specifically cardiovascular, neurological and psychological conditions. As part of this work, he conducts research at Queen Mary Hospital, Hong Kong to evaluate the safety and effectiveness of medication in patients with these and other illnesses.

Dr Chan is the Co-Principal Investigator of the programme “AI and Pharmaceuticals in Non-Communicable Diseases (NCDs)” (Programme 4) at the Laboratory of Data Discovery for Health.

She is currently an Associate Professor in the Department of Pharmacology and Pharmacy at the University of Hong Kong (HKU) as well as the research lead for the Centre for Safe Medication Practice and Research of HKU. Her main research focus is in determining the safety and effectiveness of medicines, and expanding knowledge about the application of drugs. She applies a variety of methodologies utilising innovative Big Data and interventional study designs in her areas of research interest.

She has led completed and ongoing multi-centre randomised clinical trials comparing sedative and antipsychotic drugs for the management of behavioural emergencies. Her research findings have led to changes in clinical practice guideline on drug recommendations; and improving clinical practice and patient care internationally.

Dr Cheung is the Co-Principal Investigator of the programme “AI and Pharmaceuticals in Non-Communicable Diseases (NCDs)” (Programme 4) at the Laboratory of Data Discovery for Health.

He is currently an Associate Professor in the Department of Pharmacology and Pharmacy at the University of Hong Kong. His research interests focus on precision medicine which is an emerging form of disease prediction, diagnosis, and prevention using genetics, biomarkers, and other personalised information to deliver the right treatment, to the right person, at the right time.

As the underlying cause of disease could be different among patients, the use of precision medicine should both improve patient outcomes and deliver benefits to the health service, based on patient’s individualised makeup. In addition, the use of information from research of precision medicine can also lead to new drug and biomarker discovery.

Dr Chui is the Co-Principal Investigator of the programme “AI and Pharmaceuticals in Non-Communicable Diseases (NCDs)” (Programme 4) at the Laboratory of Data Discovery for Health.

She is an Assistant Professor jointly appointed by the School of Nursing and School of Public Health at the University of Hong Kong. Her PhD work focused on the safety of oral fluoroquinolones using multi-databases. She had led the design and analysis of several studies using healthcare databases from Hong Kong, Taiwan, and the United Kingdom.

Her research work aims to utilise Big Data from multi-regional/national large healthcare databases and that collected in the community to improve public health. Her current research focuses on cardiovascular disease risk prediction and evaluation using artificial intelligence (AI), Big Data for antimicrobial resistance, and improving care of people living with dementia.

Professor Rees is the Co-Principal Investigator of the programme “AI and Pharmaceuticals in Non-Communicable Diseases (NCDs)” (Programme 4) at the Laboratory of Data Discovery for Health.

He is Dean and Professor of Cognitive Neurology in the Faculty of Life Science at the University College London (UCL). He was the Director of the UCL Institute of Cognitive Neuroscience and the Deputy Head of the Faculty of Brain Sciences at UCL. He leads a research group investigating the neural basis of human consciousness based at the ICN and the internationally renowned Wellcome Trust Centre for Neuroimaging. He set up and currently directs the UCL School of Life and Medical Sciences Academic Careers Office which provides strategic leadership for the biomedical training portfolio at UCL and talent management to investigators and students across the School.

Professor Douglas is the Co-Principal Investigator of the programme “AI and Pharmaceuticals in Non-Communicable Diseases (NCDs)” (Programme 4) at the Laboratory of Data Discovery for Health.

He is a Professor of Pharmacoepidemiology at the London School of Hygiene and Tropical Medicine. He is a pharmacoepidemiologist and previously studied physiology and completed a PhD in Manchester. Since then he has spent several years at the UK Medicines & Healthcare Products Regulatory Agency and in the pharmaceutical industry investigating adverse effects of drugs – both in clinical trials and post-marketing.

Professor Wei is the Co-Principal Investigator of the programme “AI and Pharmaceuticals in Non-Communicable Diseases (NCDs)” (Programme 4) at the Laboratory of Data Discovery for Health.

She is a Professor of Pharmacoepidemiology and Drug Safety Research at the University College London. Prior to moving to London, she was a lecturer in epidemiology and medical statistics in the Medicines Monitoring Unit (MEMO), University of Dundee and had more than 10 years’ work experience in pharmacoepidemiology and drug safety research. Her research area covers pharmacoepidemiology and drug safety, healthcare databases, drug utilisation and safety research in cardiovascular disease.

Professor Jit is the Co-Investigator of the two programmes namely “AI-Enhanced Global and Personal Health Protection” (Programme 1) and “AI and Pharmaceuticals in Non-Communicable Diseases (NCDs)” (Programme 4) at the Laboratory of Data Discovery for Health.

He is a Professor of Vaccine Epidemiology at the London School of Hygiene and Tropical Medicine. He also holds a visiting professorship at the School of Public Health at the University of Hong Kong. He works for many years at Public Health England (as well as its predecessor the Health Protection Agency), and continues to collaborate with colleagues there. His recent research focuses on understanding the Coronavirus Disease 2019 (COVID-19) pandemic and ways to mitigate it.

Dr Li is the Co-Principal Investigator of the programme “AI and Pharmaceuticals in Non-Communicable Diseases (NCDs)” (Programme 4) at the Laboratory of Data Discovery for Health.

She is currently an Assistant Professor appointed jointly by the Department of Medicine and the Department of Pharmacology and Pharmacy at The University of Hong Kong (HKU). Her primary research interests lie in health technology assessment (HTA), health economics and real-world outcome (HEOR) research using decision analytic models and electronic health records (healthcare big data). She has expertise in healthcare data analytics, cost-effectiveness assessment for healthcare interventions, and population-based health policy evaluation.

Since joining HKU in 2014, she has led and contributed to many HERO projects, all of which involves dynamic interactions with local and international academic collaorators, the local government, industry partners, NGOs and other key opinion leaders. Her recent research focuses on the projection of healthcare expenditure on depression across lifespan and the development of outcome-based risk-sharing model for innovative and curative therapies.

Dr Lau is the Co-Principal Investigator of the programme “AI and Pharmaceuticals in Non-Communicable Diseases (NCDs)” (Programme 4) at the Laboratory of Data Discovery for Health.

She is a Lecturer in Pharmacoepidemiology and Drug Safety, School of Pharmacy of the University College London. She is a statistician by background and her research focuses on using large electronic databases to answer important clinical questions regarding the effects of medications, particularly those used in cardiovascular diseases, neurological and mental health conditions.

Dr Wong is the Co-Principal Investigator of the programme “AI and Pharmaceuticals in Non-Communicable Diseases (NCDs)” (Programme 4) at the Laboratory of Data Discovery for Health.

He is an Assistant Professor of the Department of Pharmacology and Pharmacy & Department of Family Medicine and Primary Care. He received PhD from the University of Hong Kong for his work on health-related quality of life of colorectal cancer and economic evaluation of colorectal cancer screening. Prior to his PhD, He graduated with Bachelor and MPhil degrees from Department of Mathematics at HK University of Science and Technology.

His current research interests are pharmacoepidemiology, and health services research, particularly retrospective administrative database research and cost-effectiveness analysis of health care interventions. He is appointed as member of editorial board of journal ‘Primary Care Diabetes’, and statistical advisor of ‘Hong Kong Medical Journal’. He was awarded the Glasgow / HKU early career mobility fund to be visiting researcher at Health Economics and Health Technology Assessment (HEHTA), University of Glasgow in 2016, and was awarded the HMRF Research Fellowship in 2017 to be academic visitor at Health Economics Research Centre, University of Oxford in 2019.

Dr Wan is the Co-Principal Investigator of the programme “AI and Pharmaceuticals in Non-Communicable Diseases (NCDs)” (Programme 4) at the Laboratory of Data Discovery for Health.

He is currently an Assistant Professor at the Department of Pharmacology and Pharmacy & the Department of Family Medicine and Primary Care of The University of Hong Kong. He obtained his degree of B.Sc. in Computing Mathematics with First Class Honour from the City University of Hong Kong and M.Sc. in Statistics with Distinction from the University of Nottingham in UK. Following the completion of his Ph.D. in family medicine and medical statistics from the University of Hong Kong, he worked as a medical statistician in the University of Oxford. He was also a Chartered Statistician (CStat) from the Royal Statistical Society and a Professional Statistician (PStat®) from the American Statistical Association.

Eric is an experienced epidemiologist and medical statistician in health and health service research, and published several papers in international journals. Currently, he is continuing to pursue his interest in medication safety, pharmacoepidemiology, epidemiology, public health and health intervention/service using big data cohort.

Dr Lai is the Co-Principal Investigator of the programme “AI and Pharmaceuticals in Non-Communicable Diseases (NCDs)” (Programme 4) at the Laboratory of Data Discovery for Health.

He is a Research Assistant Professor at the Department of Pharmacology and Pharmacy, HKUMed. He obtained his B.Sc. degree in economics and finance from HKUST Business School in 2013 (graduating with Dean’s Award in Social Science) and his Ph.D. degree in public health from CUHK Medicine in 2019. He received the Sir Edward Youde Memorial Fellowship (for Postgraduate Students) 2018/19 in recognition of the potential societal significance of his Ph.D. research and was awarded the RGC Postdoctoral Fellowship (2020/21, inaugural exercise) in support of his postdoctoral training at the Chinese University of Hong Kong. He joined the University of Hong Kong (HKU) in 2021.

Francisco is a pharmacoepidemiologist interested in the impact of primary care services and prescriptions on adverse health outcomes among populations affected by multimorbidity and in particular, the co-existence of physical and mental disorders. He has extensive experience in analyzing large healthcare datasets to address novel important clinical research questions.

Dr Sing is the Co-Principal Investigator of the programme “AI and Pharmaceuticals in Non-Communicable Diseases (NCDs)” (Programme 4) at the Laboratory of Data Discovery for Health.

She is currently a Research Assistant Professor in the Department of Pharmacology and Pharmacy at the University of Hong Kong (HKU). Dr. Sing obtained her PhD in pharmacogenetics and pharmacoepidemiology at the University of Hong Kong. She received post-doctoral training in the Department of Pharmacology and Pharmacy, HKU, under the supervision of Dr. Ching-Lung Cheung.

Dr Sing’s research focused on the epidemiology and pharmacoepidemiology of bone-related diseases and endocrine disorders. She is interested in the safety and repurposing of medications for treatment of osteoporosis and diabetes, particularly in the oldest old population. Her expertise is in big data research using various healthcare databases.